Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

NCT03474965 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

117

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease (SCD)

Interventions

DRUG: Crizanlizumab

Sponsor

Novartis Pharmaceuticals